Biotech News
Related news
MXCTMaxCyte2026-10-14 12:05 EST
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
ABEOAbeona Therapeutics2026-09-16 11:30 EST
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
ABEOAbeona Therapeutics2026-07-21 11:30 EST
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
RCKTRocket Pharmaceuticals2026-10-06 20:12 EST
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
RCKTRocket Pharmaceuticals2026-09-03 11:00 EST
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
PHARPharming Group2026-08-13 05:00 EST
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
SNYSanofi2026-10-12 16:05 EST
Sanofi: Information concerning the total number of voting rights and shares – September 2026
OCGNOcugen2026-09-25 11:02 EST
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
CRSPCRISPR Therapeutics2026-08-28 14:31 EST
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...
Recent company news
MXCTMaxCyte2026-10-14 12:05 EST
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MXCTMaxCyte2026-09-11 20:30 EST
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCTMaxCyte2026-08-19 12:05 EST
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MXCTMaxCyte2026-08-12 20:05 EST
MaxCyte Reports Second Quarter 2026 Financial Results
Stock data
- Close
- 1.47 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States